Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib

CONTEXT: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. OBJECTIVE: The objective of the study was to determine the efficacy of salvage therapy after first...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dadu, Ramona, Devine, Catherine, Hernandez, Mike, Waguespack, Steven G., Busaidy, Naifa L., Hu, Mimi I., Jimenez, Camilo, Habra, Mouhammad A., Sellin, Rena V., Ying, Anita K., Cote, Gilbert J., Sherman, Steven I., Cabanillas, Maria E.
Formato: Artigo
Lenguaje:Inglês
Publicado: Endocrine Society 2014
Materias:
Endocrine Care
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4037722/
https://ncbi.nlm.nih.gov/pubmed/24628550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-3588
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares